SCS Hf 10 Burst denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for scs hf10 burst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny HF10/Burst SCS as Experimental

Aetna applies an "experimental or investigational" label to treatments it has determined lack sufficient evidence to meet its coverage standards. For HF10 and burst spinal cord stimulation, this denial most commonly arises when: the specific indication being treated falls outside what Aetna's medical policy has deemed established (e.g., certain non-spinal pain conditions); the clinical record does not clearly map the patient's diagnosis to an Aetna-covered indication; or Aetna's policy has not been updated to reflect the current state of evidence for a newer SCS indication. Aetna's determination of "experimental" is a policy position — it is not a definitive clinical or regulatory finding.

## Why This Denial Is Appealable

FDA device clearance, specialty society clinical guideline endorsement, and inclusion in authoritative clinical guidelines all constitute evidence that a treatment is not experimental. If HF10 or burst SCS is FDA-cleared for the patient's indication and is supported by the applicable pain medicine or neurosurgery specialty society guidelines, Aetna's "experimental" characterization is contestable. The burden is on demonstrating that the use meets the evidentiary standard Aetna's own policy requires for coverage.

## Federal Appeal Framework

• Internal appeal: File within your plan's deadline. Experimental denials often require a more robust evidentiary submission — plan for a substantive clinical argument, not just a paperwork correction.
• Physician-to-physician review: Request a peer-to-peer between the treating physician and Aetna's medical director. This is especially productive for experimental denials where clinical context matters.
• External review (ACA §2719 / ERISA §503): Experimental/investigational denials are explicitly eligible for external review. Request IRO review within 4 months of the final internal denial. The IRO independently assesses the evidence base.
• Expedited review: Available for urgent clinical situations.

## Documentation to Gather

1. FDA clearance documentation — the FDA 510(k) or PMA clearance for the specific SCS device and indication being requested. 2. Specialty society guideline references — citations (not statistics) from the applicable pain medicine, neurosurgery, or neuromodulation society guideline organizations supporting SCS for this indication. 3. Diagnosis and indication mapping — a prescriber letter explicitly mapping the patient's confirmed diagnosis to the FDA-cleared indication and the guideline-supported use. 4. Conservative treatment history — documentation that less invasive, established therapies were tried and failed, demonstrating that SCS is not a first-line experimental choice but a considered escalation. 5. Treating physician letter — a detailed letter addressing Aetna's specific evidentiary standard and citing the clinical basis for considering this therapy established rather than experimental.

## Criteria-Mapping Strategy

Obtain Aetna's published medical policy for spinal cord stimulation. Identify the exact evidence criteria Aetna uses to distinguish "established" from "experimental" coverage. For each criterion, provide a direct documentary response: FDA clearance, guideline organization endorsement, and the treating physician's clinical rationale. This structured approach demonstrates that the therapy meets Aetna's own coverage threshold.